Open AccessFirst line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir
Author(s) -
Marit G. A. van Vonderen,
Paul Lips,
Michiel A. van Agtmael,
Elly A. M. Hassink,
Kees Brinkman,
Suzanne E. Geerlings,
Jussi Sutinen,
Matti Ristola,
Sven A. Danner,
Peter Reiss
Publication year - 2009
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32832c4947
Subject(s) - ritonavir , lopinavir , lopinavir/ritonavir , medicine , lamivudine , zidovudine , urology , bone mineral , nevirapine , deoxypyridinoline , bone remodeling , gastroenterology , creatinine , endocrinology , osteocalcin , viral load , osteoporosis , chemistry , human immunodeficiency virus (hiv) , virology , alkaline phosphatase , antiretroviral therapy , hepatitis b virus , biochemistry , virus , viral disease , enzyme
We studied changes in bone mineral density (BMD) and bone turnover after initiation of combination antiretroviral therapy (cART) and the contribution of zidovudine/lamivudine (ZDV/3TC) in particular.